What this study is
The objective of this study is to evaluate the sensitivity of the DermaSensor device and Investigators when used on skin lesions concerning for melanoma.
What's being tested
- Scan with elastic scattering spectroscopy device to assess risk of malignancy
Intervention · DEVICE
Elastic scattering spectroscopy device uses a spectrum of light reflectance to compare suspicious lesion signature to that of previously scanned lesions with known benign or malignant pathology
Study details
- Sponsor
- DermaSensor, Inc.
- Conditions
- Melanoma, Skin
- Enrolling
- 396 people
- Starts
- 2024-10-08
- Est. completion
- 2027-09-10
- Design
- Single-blind, non-randomized, sequential groups
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 40 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Men or women of any ethnic group aged 40 and older
- Primary skin lesion suspicious for melanoma
- Patient is willing and able to read, understand, and sign the informed consent form (ICF)
You can't join if
- Lesion is not accessible to the DermaSensor device Handheld Unit and tip (e.g., inside ears, under nails, etc.)
- Lesion is on areas of psoriasis, eczema, acne, or similar inflammatory skin conditions that may impede appropriate DermaSensor device tip placement on the lesion.
- Lesion is greater than 15mm in diameter at the widest point.
- Lesion has a targeted area less than 2.5mm in diameter where the DermaSensor device tip cannot be placed entirely within the border of the targeted area of the lesion.
- Lesion has no contiguous area of at least 2.5mm due to ulceration, erosion or liquid discharge (e.g., blood).
- Lesion is covered by a crust or scale, and lesion surface cannot be cleared of crust or scale such that there is a contiguous area of at least 2.5mm of cleared intact skin that is free of any crust, ulceration, erosion or liquid discharge (e.g., blood).
- Lesion is obstructed by foreign matter that cannot be non-invasively removed (e.g., tattoo, splinter, etc.)
- Lesion is not completely cleared of (i.e., free of any remaining residue) dermoscopy oils, makeup, sunscreen, other topical solutions or powders, markings, and staining treatments (e.g., iodine).
- Lesion is located on acral skin (e.g., sole or palms).
- Lesion is located within 10mm of the eye.
- Lesion is on or adjacent to scars, areas previously biopsied, or areas subjected to any past surgical intervention.
- Lesion is located on mucosal surfaces (e.g. genitals, lips).
- Lesion is located in an area with acute sunburn.
- Dementia or other neurologic, physical or psychological limitation that would prevent the patient from signing informed consent and/or completing any required follow-up visits
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (2)
2 openVelocity
New Smyrna Beach, Florida, United States
- Anna Kipp · Contact
- Chang · Principal investigator
RecruitingWest Clinical Research
Morehead City, North Carolina, United States
- Luke Snedaker · Contact252-515-0050Info@westclinicalresearch.com
- Patrick Morgante · Principal investigator
Recruiting
Study team
Sponsor
DermaSensor, Inc.
Study ID CSP-24-0002
Study chair
Gary Slatko, MD, MBA
DermaSensor, Inc.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.